Cannabis Science Reports Cancer Tumors Continues to Shrink and Die as Apparent Pieces of the Dying Cancer Tumors Begin to Fall off as Evidenced in Newest Photos of the 3rd Squamous Cell Carcinoma Patient

“Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to release new updated photos from the 3rd cancer patient self-administering cannabis extracts. This patient has severe squamous cell carcinoma on their head that was resistant to chemo and radiation therapy, which left the patient with large tumor masses on their head. With these new photo updates you can see the drastic change in appearance of the tumors and how the topical cannabis extract is killing them. 

Cannabis Science has been working very closely with this patient and is continuing to see vast improvement to his treatment resistant squamous cell carcinoma. Prior to using cannabis-based extracts this patient had received radiation and chemotherapy for his condition. This patient notices a huge difference between the treatments and had stated, “While on radiation treatments, each day was stressful and after each treatment I felt horrible as if my entire body was dying organ by organ. While using the Oil, I have noticed that my overall health seems much better. I sleep the recommended hours, unlike the insomnia I suffered while on radiation, and unlike the radiation that caused the restless sleep and nightmares, on the Oil I sleep like a baby.” The patient also mentioned that while showering they would see bits and pieces of the tumor falling off with the water as he was cleaning his head.

This patient is very pleased with the results of the topical cannabis extract so far and said he enjoyed absolutely nothing about radiation and felt constantly sick and just overall unhealthy, but with using the oil he said, “I feel myself being restored, not tortured.””

More: http://www.drugs.com/clinical_trials/cannabis-science-reports-cancer-tumors-continues-shrink-die-apparent-pieces-dying-cancer-tumors-13168.html

Cannabis says success in 4th brand new self-administering cancer patient

“Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis (marijuana) products, has introduced 4th cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.

Cannabis Science has received images and documented information from this 4th patient who has basal cell carcinoma on his left nostril. The patient is enrolled in a photographic mole-mapping programme at the University of Colorado Hospital and is examined annually. The last time he was examined was in October of 2011, where his doctors found a small bump on his left nostril that was less and 1/8″ in diameter, and believed it to be basal cell carcinoma. At that time it was too early to be certain if it was in-fact basal cell carcinoma.

By January 2012 the small bump on his left nostril had grown slightly and had developed a rough scaly texture similar to his previous episodes of basal cell carcinoma. The patient began self-administering cannabis extract oil (CT-1) topically to the spot on his left nostril in the middle of January. The patient immediately reported minor irritation of the spot but that the surrounding healthy skin was not irritated. The rough scaly texture and the minor irritation disappeared by day four of treatment and by day nine of treatment the bump had shrunk considerably and was almost imperceptible to the touch. In these three images you can notice a significant reduction in the lesion.

This patient has a history of having five different episodes of basal cell carcinoma starting at the age of 27, and had one malignant melanoma at age 35. He is now 46, and has suffered from numerous severe sunburns which caused blistering and peeling. This patient was diagnosed with dysplastic nevus syndrome (over 100 atypical moles) and has been told that he is certain to have additional melanomas at some point in the future. Doctors have already confirmed that he has had basal cell carcinoma on his right jaw line, which resulted to Mohs procedure that was performed in December of 2011.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments.

 Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in.”

http://pharmabiz.com/NewsDetails.aspx?aid=67354&sid=2 

Cannabis Science extracts benefit squamous cell carcinoma cancer and skin cancer patients

“We stumbled upon this news a couple weeks back regarding Cannabis Science, Inc. (OTCBB:CBIS.OB) reported the continuing successful progress by two patients who have been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer and Skin Cancer.

According to their earlier press releases, these patients have photo-documented dramatic results that the Company will release to the public once treatment is completed and has been properly vetted by clinical biopsy. The Company, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who are seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed cancer treatment.

Cannabis has an outstanding safety profile as determined in 1988 by Federal Administrative Law Judge Francis Young who recommended cannabis be removed from Schedule I. The refusal of the DEA to follow this recommendation has resulted in 16 states allowing some form of medical marijuana access for their citizens. Numerous other states are moving in this direction. Consequently, patients in states with medical marijuana laws are able to make an informed decisions to try various state-legal cannabis preparations and to determine what is most effective for their particular condition. As a result, there is an unprecedented accumulation of “anecdotal” data.

Cannabis Science went on to mention that it’s making cannabis-based medicines available to the public as rapidly as possible.”

More: http://www.news-medical.net/news/20120107/Cannabis-Science-extracts-benefit-squamous-cell-carcinoma-cancer-and-skin-cancer-patients.aspx

Bay Area Researchers Claim Cannabis Can Cure Cancer

“Marijuana has been used for medicinal purposes–relieving stress and pain and fighting hunger and nausea–for centuries if not millennia. But now, a pair of doctors in San Francisco claim that they’ve compiled reliable data showing that a certain compound in cannabis–cannabidiol–may actually cure cancer.”

Bay Area Researchers Claim Cannabis Can Cure Cancer

“Unlike THC, the ingredient in marijuana that makes you feel stoned, cannabidiol is a non-toxic compound of the plant that has no psychoactive qualities, and it’s been the focus of an ongoing series of trials at the San Francisco-based California Pacific Medical Center. There, physicians Sean McAllister and Pierre Desprez claim they’ve successfully used cannabidiol to fight animal genes involved in the spread of cancer. Now they hope to be allowed to conduct anti-cancer research using cannabidiol on actual humans.”

Cannabinoid receptor systems: therapeutic targets for tumour intervention.

Image result for taylor & francis online

“The past decade has witnessed a rapid expansion of our understanding of the biological roles of cannabinoids and their cognate receptors. It is now certain that Delta9-tetrahydrocannabinol, the principle psychoactive component of the Cannabis sativa plant, binds and activates membrane receptors of the 7-transmembrane domain, G-protein-coupled superfamily.

Several putative endocannabinoids have since been identified, including anandamide, 2-arachidonyl glycerol and noladin ether. Synthesis of numerous cannabinomimetics has also greatly expanded the repertoire of cannabinoid receptor ligands with the pharmacodynamic properties of agonists, antagonists and inverse agonists.

Collectively, these ligands have proven to be powerful tools both for the molecular characterisation of cannabinoid receptors and the delineation of their intrinsic signalling pathways. Much of our understanding of the signalling mechanisms activated by cannabinoids is derived from studies of receptors expressed by tumour cells; hence, this review provides a succinct summary of the molecular pharmacology of cannabinoid receptors and their roles in tumour cell biology.

Moreover, there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases. Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents.” http://www.ncbi.nlm.nih.gov/pubmed/14640910

http://www.tandfonline.com/doi/abs/10.1517/14728222.7.6.749

The endocannabinoid system and its therapeutic exploitation.

Image result for Nat Rev Drug Discov.

“The term ‘endocannabinoid’ – originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands – now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.”  http://www.ncbi.nlm.nih.gov/pubmed/15340387

http://www.nature.com/nrd/journal/v3/n9/full/nrd1495.html

Active Component Of Marijuana Has Anti-Cancer Effects, Study Suggests

“Guillermo Velasco and colleagues, at Complutense University, Spain, have provided evidence that suggests that cannabinoids such as the main active component of marijuana (THC) have anticancer effects on human brain cancer cells.

In the study, THC was found to induce the death of various human brain cancer cell lines and primary cultured human brain cancer cells by a process known as autophagy.

Consistent with the in vitro data, administration of THC to mice with human tumors decreased tumor growth and induced the tumor cells to undergo autophagy. As analysis of tumors from two patients with recurrent glioblastoma multiforme (a highly aggressive brain tumor) receiving intracranial THC administration showed signs of autophagy, the authors suggest that cannabinoid administration may provide a new approach to targeting human cancers.”  http://www.sciencedaily.com/releases/2009/04/090401181217.htm

“Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells” https://www.jci.org/articles/view/37948

 

Skin Cancer Patient Says Oil From Medical Marijuana Is A Cure

“A Ferndale man claims he’s found a cure for his cancer and it’s now legal in Michigan.”

%name Skin Cancer Patient Says Oil From Medical Marijuana Is A Cure.

“WWJ’s Sandra McNeill spoke with Michael McShane who claims he’s been using a topical oil made from medical marijuana on the skin cancer on his forehead and in just over two months it’s nearly gone.

“I’ve got biopsies, chart notes, photographs … in about three weeks I’m going to go back  and really wrap this part of the case up,” said McShane. “It’s made the same way a lot of the fragrances and perfumes are made, and the oil is applied, in my case, directly to the skin, and within 10 weeks my cancer is gone.

“From a topical standpoint I don’t experience any euphoria,” said McShane.

McShane freely admits that he has smoked marijuana since he was in his teens, “It went from a party to a cure for cancer,” he said.”

Read more: http://detroit.cbslocal.com/2011/08/29/skin-cancer-patient-says-oil-from-medical-marijuana-is-a-cure/

Cannabinoid receptors as novel targets for the treatment of melanoma

“Melanoma causes the greatest number of skin cancer-related deaths worldwide. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis and metastasis, and increased apoptosis, of melanomas in mice. Cannabinoid antimelanoma activity was independent of the immune status of the animal, could be achieved without overt psychoactive effects and was selective for melanoma cells vs. normal melanocytes.

Cannabinoid antiproliferative action on melanoma cells…

 These findings may contribute to the design of new chemotherapeutic strategies for the management of melanoma.

 …the present report, together with the implication of CB2 receptors in the control of processes such as pain initiation, emesis, and inflammation, opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired psychotropic side effects.

Specifically, the antiproliferative effect of cannabinoids reported here may set the basis for a new therapeutic approach for the treatment of malignant melanoma.”

Full text: http://www.fasebj.org/content/20/14/2633.long

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors

“Cannabinoids inhibit skin tumor growth in vivo. Here we show that the CB1 and the CB2 receptor are expressed in normal skin and skin tumors of mice and humans. In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB1/CB2 agonist WIN-55,212-2 or the selective CB2 agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells.

 

Cannabinoids, the active components of Cannabis sativa linnaeus (marijuana)…

Marijuana and its derivatives have been used in medicine for many centuries, and currently there is a renaissance in the study of the therapeutic effects of cannabinoids… cannabinoids may be potential antitumoral agents owing to their ability to induce the regression of various types of tumors, including lung adenocarcinoma, glioma, and thyroid epithelioma in animal models.

This background prompted us to explore whether (a) the skin and skin tumors express cannabinoid receptors; (b) cannabinoid receptor activation exerts a growth-inhibiting action on skin tumors in vivo; and (c) inhibition of angiogenesis is implicated in the anti-tumoral effect of cannabinoids.

Our data show that (a) CB1 and CB2 receptors are present in the skin and skin tumors; (b) local cannabinoid receptor activation induces the regression of skin tumors in vivo; and (c) at least two mechanisms may be involved in this action: direct apoptosis of tumor cells and inhibition of tumor angiogenesis.

These results support a new therapeutic approach for the treatment of skin tumors.”

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151833/